Skip to Main Content

1,758

Views

5

CrossRef citations to date

0

Altmetric

Letters to the Editor

Phase I trials of the lysine-specific demethylase 1 inhibitor, GSK2879552, as mono- and combination-therapy in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes

Gail J. Roboza Weill Cornell Medicine and New York-Presbyterian Hospital, New York, NY, USAView further author information

,

Karen Yeeb Princess Margaret Cancer Center, Toronto, ON, CanadaView further author information

,

Amit Vermac Montefiore Medical Center and Albert Einstein College of Medicine, New York, NY, USAView further author information

,

Gautam Borthakurd MD Anderson Cancer Center, Houston, TX, USA

https://orcid.org/0000-0001-7679-6453 View further author information

,

Adolfo de la Fuente Burguerae MD Anderson Cancer Center, Madrid, SpainView further author information

,

Guillermo Sanzf Department of Hematology, Hospital Universitario y Politecnico La Fe, Valencia, SpainView further author information

,

Helai P. Mohammadg GSK, Collegeville, PA, USAView further author information

,

Ryan G. Krugerg GSK, Collegeville, PA, USAView further author information

,

Natalie O. Karpinichg GSK, Collegeville, PA, USAView further author information

,

Geraldine Ferron-Bradyg GSK, Collegeville, PA, USAView further author information

,

Andre Acustag GSK, Collegeville, PA, USAView further author information

,

Heather Del Buonog GSK, Collegeville, PA, USAView further author information

,

Therese Collingwoodg GSK, Collegeville, PA, USAView further author information

,

Marc Ballasg GSK, Collegeville, PA, USAView further author information

,

Arindam Dharg GSK, Collegeville, PA, USAView further author information

&

Andrew H. Weih Alfred Hospital and Monash University, Melbourne, VIC, AustraliaCorrespondence[email protected]

https://orcid.org/0000-0002-7514-3298 View further author information